Retatrutide 10 mg MediPharma

Description

Retatrutide 10 mg MediPharma — Manufactured to exacting pharmaceutical standards, this pharmaceutical-grade thermogenic compound accelerates fat metabolism and supports lean body composition during cutting phases. Enhances metabolic rate while preserving lean muscle tissue. This formulation is dosed at 10 mg per unit.

Key Benefits

• Triple agonist — GIP + GLP-1 + glucagon receptors
• Phase-2 data: ~24% body-weight reduction at 48 weeks
• Glucagon component drives thermogenesis and hepatic fat oxidation
• Currently investigational — not yet FDA-approved
• Weekly SubQ dosing with titration
• Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake

How It Works

First-in-class triple agonist combining GLP-1 and GIP incretin effects with glucagon-receptor activation. Glucagon component drives thermogenesis and hepatic lipolysis — mechanism absent from semaglutide/tirzepatide. Investigational; not approved as of 2024.

Pharmacokinetics

Plasma half-life approximately 6 days. Weekly SubQ dosing. Phase-2 data show dose-proportional exposure and stable steady-state by week 4.

Potential Side Effects

GI side-effects higher than semaglutide/tirzepatide during titration. Heart-rate elevation modest. Muscle-mass loss requires training offset. Long-term safety profile still being established — use with awareness of investigational status.

Cycle & Stacking Guide

Investigational protocol. Research-grade use only. Resistance training and high-protein diet essential for lean-mass preservation. Follow phase-2 trial titration schedule closely.

Manufacturer Notes

MediPharma produces to a standard European formulary pattern. Vial specs and carrier details are printed on every label.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.